



CDC Institutional Biosafety Committee (IBC) Meeting Minutes

Date: January 30, 2025

Time: 10:30 AM – 12:00 PM

Location: MS Teams meeting

Member	Attendance	Member	Attendance
1. NCEZID/DVBD1	<input checked="" type="checkbox"/>	13. NCEZID/DCLSR2	<input type="checkbox"/>
2. NCIRD/DVD	<input checked="" type="checkbox"/>	14. IOD/OLSS3	<input checked="" type="checkbox"/>
3. NCEZID/DHCPP1	<input checked="" type="checkbox"/>	16. NCEZID/DCLSR3	<input checked="" type="checkbox"/>
4. IOD/OLSS1	<input type="checkbox"/>	17. NCEZID/OD	<input checked="" type="checkbox"/>
5. OCOO/OSSAM/OHC	<input type="checkbox"/>	18. IOD/OLSS4	<input checked="" type="checkbox"/>
6. NCEZID/DVBD2	<input checked="" type="checkbox"/>	19. NCHHSTP/DHP2	<input type="checkbox"/>
7. IOD/OLSS2	<input checked="" type="checkbox"/>	20. Outside Member/Atlanta1	<input checked="" type="checkbox"/>
8. NCHHSTP/DHP1	<input type="checkbox"/>	21. Outside Member/Atlanta2	<input checked="" type="checkbox"/>
9. NCHHSTP/DTE	<input type="checkbox"/>	22. Outside Member/Fort Collins	<input checked="" type="checkbox"/>
10. NCIRD/ID	<input checked="" type="checkbox"/>	23. Outside Member/Puerto Rico	<input type="checkbox"/>
11. NCIRD/CORVD	<input checked="" type="checkbox"/>	24. CDC/GHC/OD	<input checked="" type="checkbox"/>
12. NCEZID/DCLSR1	<input checked="" type="checkbox"/>	Visitor(s) 5	

Agenda

1. **10:30 am EST**- Welcome.
2. Review and approval of **December 19, 2025** Meeting Minutes.
3. Review of IBC registrations:
 - 1) IBC-2025-213 Renewal
 - 2) IBC-2026-302 Renewal
 - 3) IBC-2026-303 Renewal
 - 4) IBC-2026-304 Renewal
 - 5) IBC-2026-305 Renewal
 - 6) IBC-2025-298 Renewal
4. Other Business

Principal Discussion

- Quorum confirmed.
- Meeting called to order at 10:34 am
- Review and approval of **December 19, 2025** Meeting Minutes.
- Review of IBC Registrations
- Other Business

Review of IBC Registrations

1. IBC-2025-213 Renewal

General Project Description: Hepatitis A virus (HAV) evades cellular suicide/autophagy, in the host. We will examine autophagy in HAV infected cells to determine whether HAV alters autophagy. Understanding this process may allow us to modify autophagy and reduce the time to plaque formation for HAV.

Approximate percentage of the viral genome used: N/A

Applicable Sec of NIH Guidelines: III-D-2-a, III-D-3-a

Required biological containment level for the work to be implemented: BSL-2

General Points discussed:

- **Sections 1.3 and 3.0** - Please list the specific strains of *E.coli* they are using to ensure they are K12. As written, just listing *E. coli* is not sufficient

Committee Action: Approved with changes

2. IBC-2026-302 Renewal

General Project Description: Recombinant Burkholderia pseudomallei (Burk) antigen production for use in Melioidosis serological assay development, including ELISAs and multiplexed Luminex assays.

Approximate percentage of the viral genome used: N/A

Applicable Sec of NIH Guidelines: III-D-2-a

Required biological containment level for the work to be implemented: BSL-2, BSL-3

General Points discussed:

- **Section 3** - Lists Top10 and BL21. Top 10 is a K12-derived strain and is exempt. BL21 is not. Select "No" for Section 3.3, then complete the rest of the sections on the form

Committee Action: Approved with changes

3. IBC-2026-303 Renewal

General Project Description: We are utilizing SARS-CoV-2 reporter viruses, including nano-luciferase-tagged variants, as well as SARS-CoV-2 mRNA vaccines obtained from commercial sources, internal teams, or external collaborators for research on animal pathogenicity, transmission, antiviral assessment, and immunization.

Approximate percentage of the viral genome used: >2/3

Applicable Sec of NIH Guidelines: III-D-1-a, III-D-2-a, III-D-3-a, III-D-4-b

Required biological containment level for the work to be implemented: BSL-2, BSL-3

General Points discussed:

- **Section 1.3:** referenced IACUC protocols 3380 and 3340, but only 3340 is listed in section 2.9c. Please include 3380 in 2.9c

Committee Action: Approved with changes

4. IBC-2026-304 Renewal

General Project Description: Toremfene inhibits Ebola virus entry into cultured cells, but the exact mechanism is unclear. To understand the mechanism, we have identified a mutation associated with growth in the presence of toremifene. Using surrogate systems that mimic Ebola virus glycoprotein function, we wish to confirm if the L569F change does indeed confer a reduced susceptibility to inhibition by toremifene.

Approximate percentage of the viral genome used: <1/2

Applicable Sec of NIH Guidelines: III-D-2-a, III-D-2-b, III-D-3-a, III-F-8

Required biological containment level for the work to be implemented: BSL-2

Committee Action: Approved As Written

5. IBC-2026-305 Renewal

General Project Description: This study will evaluate efficacy and mechanisms of influenza vaccines and influenza/COVID-19 combination vaccines in transgenic mouse models.

Approximate percentage of the viral genome used: N/A

Applicable Sec of NIH Guidelines: III-D-3-a, III-D-3-b, III-D-4-b, III-D-7-b

Required biological containment level for the work to be implemented: BSL-2, BSL-2E, BSL-2, BSL-3E

General Points discussed:

- **Section 3:** Change III-E to "Yes", and then select "Yes" for III-E-3, as shown in the screenshot below

Committee Action: Approved with changes

6. IBC-2025-298 Renewal

General Project Description: The goal of this project is to use a reverse genetic approach for Rift Valley fever virus to further characterize the molecular determinants of pathogenesis, and to continue the progress toward licensing our vaccine candidate for use in livestock and humans.

Approximate percentage of the viral genome used: >2/3

Applicable Sec of NIH Guidelines: III-D-1-b, III-D-2-a, III-D-3-b, III-D-4-b

Required biological containment level for the work to be implemented: BSL-2, BSL-3E

General Points discussed:

- **Section 1.3** - bullet 2 mentions BSL3E and animal work that should be 'ABSL-3E'
- **Section 4.3** - The last justification confuses me as written based on the question being asked. Perhaps edit: ' While BSL-3 is the proper containment for the WT viruses, we will perform these experiments in our BSL-3E laboratories?'

Committee Action: Approved with changes

Other Business

- **Lab Incident Update** – NIH recommended no further action is needed.
- **IBC Charter Update** - The IBC Charter Working Group has completed the draft revision. A full draft will be shared with the committee for feedback before routing to the OLSR Director for review and approval.
- **Community Member Access** – All four community members had their access restored to IBC meetings.
- **CDC IBC Meeting Minutes Publication**
 - [CDC internet for membership roster and minutes publication](#)
- Meeting adjourned at 11:47am.

REYNOLDS M. SALERNO
-S

Digitally signed by
REYNOLDS M.
SALERNO -S
Date: 2026.04.20
11:31:34 -04'00'

Reynolds M Salerno, PhD

Director, Office of Laboratory Systems and Response